Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
New research on HIV/AIDS from L.X. Liu and co-authors summarized
March 12th, 2008
"To develop an effective vaccine against the most prevalent HIV strain ''B '/C recombinant'' in China, we compared the immunogenicity of B '/C-derived gp140 and gp145. The codon optimized gp140 and gp145 env gene derived from CN54, an ancestor-like B '/C recombinant strain, were synthesized and cloned into a plasmid as DNA vaccines, designated as pDRVISV140 and pDRVISV145, respectively," researchers in Beijing, People's Republic of China report. "BALB/c mice were inoculated three times at week 0, 2, and 4 and sacrificed at week 7. Both T cell immunity and humoral immunity were determined. The mock vector pDRVISV1.0 carrying no HIV immunogen was included as control. Our...
Source: Vaccine Weekly (2008-03-12)
|
